May 30, 2024
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
May 20, 2024
Compugen Reports First Quarter 2024 Results
May 16, 2024
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
May 15, 2024
Compugen Appoints David Silberman as Chief Financial Officer
May 06, 2024
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
Apr 25, 2024
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
Apr 10, 2024
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Apr 03, 2024
Compugen to Participate in Two Upcoming Investor Conferences
Mar 11, 2024
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
Mar 05, 2024
Compugen Reports Fourth Quarter and Full Year 2023 Results
Feb 20, 2024
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
Feb 25, 2021
Compugen Announces Data Update from COM701 Phase 1 Clinical Trial
Feb 22, 2021
Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo®
Feb 16, 2021
Compugen to Release Fourth Quarter and Full Year 2020 Results on Thursday, February 25, 2021
Dec 23, 2020
Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products
Nov 10, 2020
Compugen to Present at Upcoming Investor Conferences
Nov 02, 2020
Compugen Further Expands Patent Portfolio for TIGIT Inhibitor COM902 with Composition of Matter Patent in China
Oct 27, 2020
Compugen Presents New Research Data Further Supporting PVRIG as a Potentially Promising Target for Cancer Immunotherapy
Oct 22, 2020
Compugen to Release Third Quarter 2020 Results on Thursday, November 5, 2020
Sep 30, 2020
Compugen Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its Scientific Advisory Board